Neurogene (NASDAQ:NGNE) Issues Quarterly Earnings Results

Neurogene (NASDAQ:NGNE) posted its earnings results on Monday. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.05, Zacks reports.

Neurogene Trading Down 1.8 %

Shares of Neurogene stock opened at $13.96 on Tuesday. Neurogene has a 12-month low of $13.47 and a 12-month high of $74.49. The firm’s 50-day moving average price is $17.09 and its two-hundred day moving average price is $29.30.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of Neurogene in a research report on Monday, November 25th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $60.80.

Insider Transactions at Neurogene

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the transaction, the chief financial officer now owns 72,343 shares in the company, valued at approximately $1,225,490.42. This trade represents a 5.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 9.92% of the stock is currently owned by insiders.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.